ArriVent BioPharma (ArriVent BioPharma) Cash-to-Debt : 1,113.66 (As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is ArriVent BioPharma Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. ArriVent BioPharma's cash to debt ratio for the quarter that ended in Mar. 2024 was 1,113.66.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, ArriVent BioPharma could pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

The historical rank and industry rank for ArriVent BioPharma's Cash-to-Debt or its related term are showing as below:

AVBP' s Cash-to-Debt Range Over the Past 10 Years
Min: 474.41 Med: 1790.52 Max: No Debt
Current: 1113.66

During the past 3 years, ArriVent BioPharma's highest Cash to Debt Ratio was No Debt. The lowest was 474.41. And the median was 1790.52.

AVBP's Cash-to-Debt is ranked better than
87.2% of 1523 companies
in the Biotechnology industry
Industry Median: 6.46 vs AVBP: 1113.66

ArriVent BioPharma Cash-to-Debt Historical Data

The historical data trend for ArriVent BioPharma's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

ArriVent BioPharma Cash-to-Debt Chart

ArriVent BioPharma Annual Data

Trend

Dec21

Dec22

Dec23

Cash-to-Debt

No Debt

1,175.34

474.41

ArriVent BioPharma Quarterly Data
	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash-to-Debt	Get a 7-Day Free Trial				N/A	2,405.71	3,780.89	474.41	1,113.66

Competitive Comparison of ArriVent BioPharma's Cash-to-Debt

For the Biotechnology subindustry, ArriVent BioPharma's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ArriVent BioPharma's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ArriVent BioPharma's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where ArriVent BioPharma's Cash-to-Debt falls into.

ArriVent BioPharma Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

ArriVent BioPharma's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	150.389	/	(0.14	+	0.177)
	=	474.41

ArriVent BioPharma's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	317.393	/	(0.147	+	0.138)
	=	1,113.66

ArriVent BioPharma (NAS:AVBP) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

ArriVent BioPharma Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of ArriVent BioPharma's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

ArriVent BioPharma (ArriVent BioPharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ArriVent BioPharma Inc (NAS:AVBP) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. They seek to utilize our team's deep drug development experience to maximize the potential of our lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.

ArriVent BioPharma (ArriVent BioPharma) Headlines

From GuruFocus

ArriVent Appoints Kristine Peterson to its Board of Directors

By Marketwired • 04-22-2024